Intelliheart tests in Amcal pharmacies
Friday, 13 June, 2008
IM Medical (ASX: IMI) has reached an exclusive agreement with Sigma Pharmaceuticals that will see the Intelliheart cardiac risk assessment tests sold through Sigma's Amcal network.
The Amcal network includes over 700 Amcal, Amcal Max and Guardian pharmacies throughout the country.
The product will initially be rolled out to over 200 pharmacies throughout Victoria in July. Stores in other states will begin stocking the product in the next few months.
Under the agreement Sigma has the right to produce and market other products using the Intelliheart brand name.
Intelliheart is the only widely available diagnostic which tests for both heart rate variability and arterial stiffness.
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
